• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Enlivex Ltd.

    3/13/26 4:17:47 PM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENLV alert in real time by email
    S-8 1 ea0281372-s8_enlivex.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on March 13, 2026

    Registration No. 333-             

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

     

    Enlivex Ltd.
    (Exact name of registrant as specified in its charter)

     

    Israel   Not Applicable

    (State or other jurisdiction of
    incorporation or organization)

      (I.R.S. Employer
    Identification No.)

     

     

     

    14 Einstein Street
    Nes Ziona, Israel
      7403618
    (Address of Principal Executive Offices)   (Zip Code)

     

     

     

    Enlivex Therapeutics Ltd.

    (Former name, former address, and former fiscal year, if changed since last report)

     

     

     

    Enlivex Therapeutics Ltd. Global Share Incentive Plan (2019)

    (Full title of the plan)

     

     

     

    Cogency Global Inc.

    122 East 42nd Street, 18th Floor

    New York, New York 10168

    (Name and address of agent for service)

     

    (212) 947-7200
    (Telephone number, including area code, of agent for service)

     

     

     

    Copy to:

     

    Drew M. Altman, Esq. Sharon Rosen, Adv.
    Win Rutherfurd, Esq. FISCHER (FBC & Co.)
    Greenberg Traurig, P.A. 146 Menachem Begin Street Tel Aviv
    333 S.E. 2nd Avenue, Suite 4400 6492103, Israel
    Miami, Florida 33131 +972 -3-6944111
    (305) 579-0500  

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☐
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

     

    This Registration Statement on Form S-8 is being filed by Enlivex Ltd., a company organized under the laws of the State of Israel (the “Registrant”), for the purpose of registering a total of 22,700,851 additional ordinary shares, par value NIS 0.40 per share (“Ordinary Shares”), issuable under the Enlivex Therapeutics Ltd. Global Share Incentive Plan (2019) (as amended, the “Plan”).

     

    Pursuant to Instruction E of Form S-8, the contents of the Registrant’s prior registration statement on Form S-8 registering Ordinary Shares under the Plan (File No. 333-256799) (the “Prior Registration Statement”) are hereby incorporated by reference herein, and the information required by Form S-8 is omitted, except that the provisions contained in Part II of the Prior Registration Statement are modified as set forth in this Registration Statement.

     

    1

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.  Incorporation of Documents by Reference.

     

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (the “Commission”), other than, in each case, documents or information deemed to have been furnished and not filed in accordance with Commission rules:

     

    (a)The Registrant’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Commission on April 30, 2025;

     

    (b)The Registrant’s Current Reports on Form 6-K filed with the Commission on May 30, 2025, August 18, 2025, August 18, 2025 (two reports), August 29, 2025, November 14, 2025, November 18, 2025, November 24, 2025, November 24, 2025 (two reports), November 26, 2025, December 18, 2025, January 23, 2026, February 5, 2026 and February 23, 2026; and

     

    (c)The Registrant’s Registration Statement on Form 8-A (File No. 001-36578), filed with the Commission on July 28, 2014, in which there is described the terms, rights and provisions applicable to our ordinary shares, including any amendment or report filed for the purpose of updating such description, including the description of ordinary shares filed as Exhibit 2.1 to our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Commission on April 30, 2024.

     

    Additionally, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (not including any information that is identified as “furnished” rather than filed, which information is not incorporated by reference herein), prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated herein by reference and to be a part of the Registration Statement from the date of filing of such documents. The Registrant may also incorporate any Form 6-K subsequently filed or furnished by it to the Commission prior to the filing of any such post-effective amendment, by identifying in such Form 6-K that it is being incorporated by reference herein, and any Forms 6-K so identified shall be deemed to be incorporated herein by reference and to be a part of the Registration Statement from the date of filing or furnishing of such Form 6-K. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of the Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document that also is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of the Registration Statement.

     

    II-1

     

     

    Item 8.  Exhibits.

     

    The following are the exhibits required by Item 601 of Regulation S-K:

     

    Exhibit

    Number

      Description
         
    1.1  

    Amended Articles of Association of the Enlivex Ltd. (filed as Exhibit 99.1 to the Registrant’s Report on Form 6-K, filed with the SEC on February 5, 2026, and incorporated by reference herein).

         
    5.1*  

    Opinion of Fischer (FBC & CO.). 

         
    23.1*  

    Consent of Yarel + Partners, independent registered certified public accounting firm. 

         
    23.3*  

    Consent of Fischer (FBC & CO.) (included in Exhibit 5.1). 

         
    24.1*  

    Power of Attorney (included on signature page hereto). 

         
    99.1  

    Enlivex Therapeutics Ltd. Global Share Incentive Plan (2019) (filed as Exhibit 4.3 to the Registrant’s Annual Report on Form 20-F, filed with the SEC on April 30, 2020 and incorporated by reference herein). 

         
    107.1*   Filing Fee Table.

     

    *Filed herewith.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Nes-Ziona, State of Israel, on March 13, 2026.

     

      ENLIVEX LTD.
       
      By: /s/ Oren Hershkovitz
        Name:  Oren Hershkovitz
        Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Shai Novik and Shachar Shlosberger, and each of them any of whom may act without joinder of the other, with full power to act as such person’s true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign this Registration Statement, and any and all amendments thereto (including post-effective amendments), and to file the same, with exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agent or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Name   Title   Date
             
    /s/ Oren Hershkovitz   Chief Executive Officer   March 13, 2026
    Oren Hershkovitz    (Principal Executive Officer)    
             
    /s/ Shachar Shlosberger   Chief Financial Officer   March 13, 2026
    Shachar Shlosberger   (Principal Financial and Accounting Officer)    
             
    /s/ Shai Novik   Chairman of the Board of Directors   March 13, 2026
    Shai Novik        
             
    /s/ Abraham Havron   Director   March 13, 2026
    Abraham Havron        
             
    /s/ Gili Hart, Ph.D.   Director   March 13, 2026
    Gili Hart, Ph.D.        
             
    /s/ Roger Pomerantz   Director   March 13, 2026
    Roger Pomerantz, M.D.        
             
      Director  
    Matteo Renzi        

     

    II-3

     

     

    Signature of Authorized U.S. Representative of Registrant

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Enlivex Ltd., has signed this Registration Statement on March 13, 2026.

         
      By: /s/ Colleen De Vries
      Name: Colleen De Vries
      Title:  Sr. Vice President on behalf of Cogency Global Inc.

     

    II-4

     

    Get the next $ENLV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENLV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ENLV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Enlivex Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Enlivex Therapeutics with a rating of Buy and set a new price target of $33.00 from $22.00 previously

    3/2/21 6:56:26 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENLV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt

         According to the Rain Foundation, anyone using OpenClaw or other AI agents can generate a live prediction market via a single prompt to the agent, without manual coding or centralized gatekeepers     The Rain Foundation announced a $5 million grant program to support developers and creators worldwide in building, launching, and monetizing their own independent prediction markets via the Rain decentralized platform through AI agents Nes-Ziona, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or "the Company")), a quality longevity company powered by a prediction markets treasury, today reported that the Rain Foundation, which independently oversees the d

    3/26/26 8:30:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48

    Earnings Driven by Treasury and Treasury-Related Asset Appreciation Nes-Ziona, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or "the Company")) today reported financial results and business highlights for the year ended December 31, 2025. Net income for the year ended December 31, 2025 was $1.23 Billion and diluted earnings per ordinary share (EPS) was $25.48, driven by appreciation in the valuation of the Company's treasury and treasury-related derivative assets. Enlivex is a quality longevity Company powered by a Prediction Markets Treasury, reflecting the Company's dual strategy spanning quality longevity therapeutics and prediction markets infrastru

    3/25/26 8:30:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program

    $21 Million debt financing, convertible to ENLV ordinary shares at fixed $2.69175 per share, a 264% premium to the Nasdaq closing price on March 20, 2026, with a single institutional investorThe Company exercised an option to acquire additional 3,030,303,030 RAIN tokens at $0.0033 per token, a 62% discount to its closing price on March 22, 2026, for a total aggregate purchase amount of $10 millionThe Company and the Rain Foundation, which independently oversees the Rain decentralized prediction markets protocol, extended the duration of the option to acquire up to an additional 272,121,212,121 of RAIN tokens at a purchase price of $0.0033 per RAIN token from November 30, 2026 to December 31,

    3/24/26 8:30:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENLV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Enlivex Ltd.

    3 - Enlivex Ltd. (0001596812) (Issuer)

    3/18/26 7:14:20 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Enlivex Ltd.

    3 - Enlivex Ltd. (0001596812) (Issuer)

    3/18/26 7:15:21 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Enlivex Ltd.

    3 - Enlivex Ltd. (0001596812) (Issuer)

    3/18/26 7:13:06 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENLV
    SEC Filings

    View All

    SEC Form 6-K filed by Enlivex Ltd.

    6-K - Enlivex Ltd. (0001596812) (Filer)

    3/26/26 8:32:01 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Enlivex Ltd.

    20-F - Enlivex Ltd. (0001596812) (Filer)

    3/25/26 8:40:17 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Enlivex Ltd.

    6-K - Enlivex Ltd. (0001596812) (Filer)

    3/25/26 8:31:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENLV
    Leadership Updates

    Live Leadership Updates

    View All

    Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

    Enlivex Announced today $212,000,000 private placement to initiate world's first prediction markets digital asset treasury strategy, via RAIN token accumulation NESS ZIONA, Israel, Nov. 24, 2025 /PRNewswire/ -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV) today announced the appointment of Mr. Matteo Renzi, former Prime Minister of Italy, to the board of directors at Enlivex, effective November 24th. 2025. Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) for the purchase and sale of 212,000,000 ordinary shares (or ordinary share equi

    11/24/25 10:00:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

    - Upon the closing of the private placement, Enlivex will adopt the world's first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. - RAIN is a fully decentralized predictions and options protocol that redefines predictive market ecosystems and provides a powerful platform for on-chain market creation - built for transparency, automation, and community participation. - Mr. Matteo Renzi, former Prime Minister of Italy, will be appointed to the Enlivex Board of Directors following closing of the private placement. - Enlivex to continue clinical development of Allocetra™, a potentially game-changing knee osteoarthritis therapeutic, a growing market w

    11/24/25 7:55:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

    YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound. "We are delighted to welcome Shmulik, a distinguished industry executive, to our team. Dr. Hess joins MediWound during a crucial phase of expansion as we diligently implement our global strategy. Given Shmulik's outstanding track record in international o

    11/21/23 7:00:00 AM ET
    $ENLV
    $MDWD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $ENLV
    Financials

    Live finance-specific insights

    View All

    Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development

    Nes-Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, "Enlivex" or "the Company")), today announced that it will host a virtual fireside chat on Thursday, December 11, 2025 at 11:00 am ET. Shai Novik, Executive Chairman of Enlivex, will provide an update on the Company's plans following its recently closed $212,000,000 private placement. Mr. Novik will discuss the launch of Enlivex's digital asset treasury strategy built around RAIN token accumulation as well as the Company's plans to continue to advance the clinical development of AllocetraTM. Virtual Fireside Chat Details Date: December 11, 2025Time: 11:00 am ETRegistration Link:https://shorturl

    12/4/25 8:00:00 AM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c

    1/10/25 9:00:00 AM ET
    $BIAF
    $ENLV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and Biotricity, Inc. (NASDAQ:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Enlivex Therapeutics: https://www.redchip.com/assets/access/enlv_accessBiotricity: https://www.redchip.com/assets/access/btcy_accessOren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update.

    7/19/24 9:00:00 AM ET
    $BTCY
    $ENLV
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ENLV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Enlivex Therapeutics Ltd.

    SC 13G - Enlivex Therapeutics Ltd. (0001596812) (Subject)

    11/14/24 3:29:35 PM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care